My bowel had to be removed after years of constipation
Kathryn Nicklas, 26, was told for several years that her constipation was caused by irritable bowel syndrome (IBS) and she was repeatedly prescribed laxatives.
She said embarrassment about her symptoms as a teenager meant she had struggled to advocate for her condition to be taken seriously.
Prof Julie Cornish, a leading pelvic health doctor, said many patients required surgery for pelvic health problems but that simpler solutions were possible when symptoms were spotted sooner.
'I wouldn't poo if my husband was at home'
Women 'scared to laugh or sneeze' due to incontinence
Ms Nicklas, who works in north Wales, said before her surgery she was "taking laxatives like they were smarties" but "still struggling to go to the toilet".
"I was forever living in floaty dresses because of the bloating and even bought maternity jeans just to be comfortable," she said.
"If I was able to go [for a poo] it would only be as a result of irrigation or an enema. I'd come home from work and spend an hour on the toilet – I had no life, because I was always uncomfortable."
She added: "On one occasion I didn't go to the toilet for four weeks and was admitted to hospital.
"They said I was so full of poo, everything had just stopped working."
Despite various tests and changes to her diet, no cause was ever found, but years of constipation had a long lasting impact on Ms Nicklas' pelvic organs – causing pain, vaginal bleeding and bloating.
Ms Nicklas' large bowel was removed in 2022.
As an adult, Ms Nicklas said she advocated for her symptoms to be taken seriously, but as a teenager she said embarrassment about bodily functions had made that more difficult.
"Looking back now, why is that such an embarrassing thing?
"Why is going to the toilet so embarrassing when it's just a normal function that everybody does?
"Would my constipation have been better if I hadn't have refused to go to the toilet unless I was at home and my brothers weren't around and no one could hear me? Because that's not healthy decision making," she added.
"As a result of the constipation and so many years of it my body's been affected.
"Your pelvic floor gets absolutely destroyed by the fact that you're constantly trying to go but you can't go."
Prof Cornish, a colorectal surgeon, said pelvic health issues affected both men and women.
"It is a public health issue that actually we need to be giving information to people at an earlier stage – and it's not just women and girls, it's also boys and men because pelvic health issues affect everybody in different ways," she said.
"We're not just talking about gynaecological bits, we're talking about the bladder and bowel which can be impacted and that does have a bearing on things like pelvic organ prolapse.
"So if you are chronically constipated for many years you are far more likely to develop problems with a prolapse."
The need for better understanding is part of the reason why Prof Cornish set up the Everywoman health festival in Cardiff, which is now in its third year.
A thousand tickets will be given free to teenagers this year, with educational sessions planned on menstrual health, pelvic health and knowing basic body parts.
Shakira Hassan, a specialist women's health physiotherapist, treats a wide range of conditions including pelvic pain, bladder, bowel and prolapse issues, where pelvic organs have lowered out of place.
"If you were to examine most women over 40, 50% of those women will actually have a pelvic organ prolapse, so it's about being able to educate and empower those women to be able to still lead a really normal and well life," she said.
Ms Hassan said stigma was a huge factor, which could be worse in some cultures.
"We know that potentially one in three women will experience some urinary incontinence and potentially one in four women will experience some level of faecal incontinence throughout their life. That's huge numbers – it's really common."
"Education is key," said Prof Cornish.
"And the difficulty is that whilst there are some people who have that understanding or are able to access that education, you're essentially disenfranchising a large proportion of the population who may not be able to access it, and they may end up being the patients that I see more of.
"You see the inequalities that are out there.
"But all of this leads to a massive delay in treatment and usually an increase in the severity of symptoms and treatments needed.
"We all have a responsibility for our own health and that is going to be key – it's not just about off-loading it to the NHS, so I think the more we teach our children, that's going to empower them to take responsibility going forward."
The Welsh government said: "Health and wellbeing is a mandatory part of the curriculum for Wales and helps learners to understand different factors that affect their physical health.
"Our guidance expects children to learn about a range of health conditions that can affect them."
'I want my womb removed but doctors say I'm too young'
Cut wait times for extra cash, FM warns health bosses
'I discovered my fat build-up condition after a Love Islander had it'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fast Company
11 minutes ago
- Fast Company
Wegovy and Zepbound patients are resorting to these cost-saving measures to stay on the weight-loss drugs
Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but as more U.S. insurers restrict coverage people are trimming costs by stretching doses or forgoing expenditures like vacations to pay for the medication out of pocket. A half dozen doctors who spoke with Reuters said insurance coverage has tightened in 2025 as many employers drop it for the expensive GLP-1 drugs. While patients on these medications are counseled on proper diet and exercise, clinical trials show that people who stop taking these drugs are apt to regain weight. Novo Nordisk's Wegovy and Eli Lilly's Zepbound are weekly injections with U.S. insurer list prices of more than $1,000 a month. For customers willing to pay cash, both drugmakers will ship directly for $499 a month if refills are purchased at fixed intervals. 'A significant number of my patients now pay cash,' said Dr. Nidhi Kansal, an obesity specialist at Northwestern Medicine in Chicago. 'People find a way to scrounge up $6,000 a year, which sucks, because that's a vacation or two.' Subscribe to the Daily newsletter. Fast Company's trending stories delivered to you every day Privacy Policy | Fast Company Newsletters More than a billion people worldwide are obese, according to the U.N. World Health Organization, which has said the GLP-1 drugs could help end the obesity pandemic. 'A KIND OF PURGATORY' A tech industry job change for Yelena Kibasova, a 40-year-old who lives in the Minneapolis area, meant loss of coverage for her Zepbound prescription that helped her achieve and maintain a 150-pound (68-kg) weight loss. GLP-1 patient Yelena Kibasova, 40, poses in this undated handout picture. [Photo: @morethanmyweight/Handout via Reuters] 'My new company does not cover GLP-1s, so now I am in a kind of purgatory,' Kibasova said. 'I stopped doing my nails. I stopped doing my hair. Those things are not as important as me staying at a healthy weight.' The doctors interviewed by Reuters said patients once leery about long-term obesity treatment are now more comfortable staying on a drug. The doctors said that conversations about temporary use happen only when a patient is trying to lose a certain amount of weight for issues such as fertility treatment or an organ transplant. These obesity specialists said they are hopeful that competition will help bring down prices as new weight-loss options emerge, including new oral drugs that may be available next year. Lilly last week announced trial results for its easier-to-manufacture pill, which was shown to cut patient weight by 12.4%, a few percentage points less than injected drugs. The company hopes to launch it in August 2026. Kenneth Custer, Lilly's head of cardiometabolic health, told Reuters the pill is being tested in several settings, including as a maintenance therapy. Custer declined to comment on how it might be priced. MEDICATION FOR MAINTENANCE Dr. Anne Peters, an endocrinologist at Keck Medicine USC in Los Angeles, said it is important that patients who reach their weight-loss goal not stop a prescription 'cold turkey,' so the dose can be tapered down over several months. Peters said about a third of her patients are able to reduce their dose and maintain weight loss, while the rest need to stay on the medication. An analysis of U.S. pharmacy insurance claims found that nearly two-thirds of patients who started on Wegovy or Zepbound in 2024 were still on the medications a year later. advertisement Peters said she uses 'every technique in the book' to secure insurance coverage for patients, but noted that a growing number of plans no longer pay for the treatments, and patients have to pay out-of-pocket. U.S. pharmacies supply self-injection pens pre-loaded with doses of Wegovy or Zepbound. Lilly's direct-to-consumer service also offers vials. 'Some patients can stretch out the vials longer. Get 15 mg, and then give a 10 mg dose for instance,' Dr. Peters said, noting that the drug's instructions advise that such an approach should not be taken. Doses of 5 mg, 10 mg and 15 mg are recommended for weight-loss maintenance. Patients also are turning to lower-cost compounded versions of the GLP-1 drugs, or are even mixing them at home with raw ingredients, both of which Peters and other doctors advise against due to safety concerns. Dr. Angela Fitch, former president of the Centennial, Colorado-based Obesity Medicine Association and chief medical officer at online primary care provider Knownwell, said nobody wants to be on a medication, but patients who respond to a GLP-1 drug 'really don't want to go off of it when they recognize that it has such a value to them.' Both Wegovy and Zepbound were first launched, under the brand names Ozempic and Mounjaro, as diabetes treatments. The class has been linked to a range of benefits, including improved heart health and less sleep apnea. Fitch said the most common reason for her patients to stop taking a GLP-1 drug is loss of insurance coverage. She said her experience is that about 10% of patients are able to reach a target weight and maintain it without further treatment. 'We are in a dip where people are dropping coverage,' Fitch said, adding that the direct-to-consumer options are an 'upper-ish middle-class thing.' —Deena Beasley, Reuters
Yahoo
an hour ago
- Yahoo
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB
The Saudi Arabia Osteoporosis Drugs Market is projected to grow from US$ 210.89 million in 2024 to US$ 308.84 million by 2033, with a CAGR of 4.33% from 2025. Major growth drivers include an aging population, increasing osteoporosis rates, and favorable healthcare regulations. While bisphosphonates remain popular for their cost-effectiveness, biologics are expected to see the fastest growth. Government initiatives under Vision 2030 support local drug production and healthcare infrastructure, enhancing drug accessibility. However, challenges such as low adherence and rural access remain. Key market players include Amgen, Eli Lilly, and Pfizer. Saudi Arabian Osteoporosis Drugs Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Osteoporosis Drugs Market to Reach US$ 308.84 Million by 2033 - 4.33% CAGR Driven by Biologics and Aging Population" report has been added to Saudi Arabia Osteoporosis Drugs Market is expected to reach US$ 308.84 million by 2033 from US$ 210.89 million in 2024, with a CAGR of 4.33% from 2025 to 2033 Due to improved healthcare infrastructure, the Saudi Arabian market for osteoporosis medications is concentrated in urban areas like Riyadh, Jeddah, and Dammam, whereas rural areas have less access to experts, diagnostics, and treatment alternatives. Growing rates of osteoporosis, the quick uptake of biologics, and advantageous healthcare laws in a number of Saudi Arabian nations are the main causes of this expansion. While bisphosphonates continue to dominate in volume due to their cost effectiveness, the biologics segment is anticipated to grow at the quickest rate. Government programs under Vision 2030, which prioritize regional medication production and improved healthcare infrastructure, promote the pharmaceutical industry. Osteoporosis treatments are becoming more accessible and reasonably priced as a result of these initiatives, and both name brand and generic medications are essential in satisfying the rising calcitonin, parathyroid hormone analogs, selective estrogen receptor modulators (SERMs), and monoclonal antibodies are among the available treatments. Newer biologic medicines are steadily gaining traction because of their increased efficacy and better patient outcomes, even if bisphosphonates are still frequently administered. Despite progress, issues like poor drug adherence, low awareness in rural regions, and underdiagnosis still exist. Additionally, comprehensive nationwide screening programs and coordinated post fracture care are lacking. Reducing the long term economic cost of osteoporosis in the nation and improving treatment outcomes could be achieved by addressing these challenges through integrated care models, digital health technologies, and Factors Driving the Saudi Arabia Osteoporosis Drugs Market Growth Saudi Arabia's Aging Population Is GrowingBecause osteoporosis and aging are closely related, Saudi Arabia's aging population is a major factor driving up demand for osteoporosis medications. People are more susceptible to fractures, loss of bone density, and associated problems as they get older, especially those over?60. The need for long term therapeutic treatments as well as preventive measures is growing as a result of this demographic shift. More people are reaching the age range where osteoporosis becomes a major concern due to better healthcare and longer life expectancies. As a result, the incidence of osteoporosis is rising in areas with greater populations of elderly persons. In order to assist the aging population and lessen the health burden associated with fractures, this development emphasizes the urgent need for efficient drugs and healthcare Rates of Screening and DiagnosisEarly osteoporosis identification has increased throughout Saudi Arabia thanks to the availability of sophisticated diagnostic technologies including dual energy X ray absorptiometry (DEXA) and bone mineral density (BMD) scanning. These technologies are now widely used in hospitals and clinics, increasing screening accessibility for high risk populations, especially postmenopausal women. In order to encourage early testing and diagnosis, health authorities are aggressively promoting awareness and screening initiatives. Because of this, more people are being diagnosed with bone loss early on, when treatment can be most successful. The number of patients eligible for osteoporosis treatments has increased dramatically due to the increase in early detection, which has increased demand for pharmacological interventions and made it possible to control the condition more effectively over the long Initiated Medical ProgramsAs a national health issue, osteoporosis is being actively addressed by the Saudi Arabian government. It seeks to lower the frequency of fractures and enhance bone health outcomes through education programs, public health campaigns, and preventative measures. Osteoporosis screening and bone density monitoring are becoming more commonplace in national health programs, and access to therapies is being facilitated by drug reimbursement policies and subsidized treatment options. These programs are promoting earlier medical intervention and increasing treatment adherence. Additionally, by making strategic investments in public health, the government's Vision 2030 push for local pharmaceutical development and a larger healthcare infrastructure is bolstering the availability of osteoporosis medications and promoting long term market in the Saudi Arabia Osteoporosis Drugs Market Low Persistence and Adherence to TreatmentLow patient adherence and persistence with prescribed medication regimens is one of the main issues facing Saudi Arabia's osteoporosis management. A lack of immediate, apparent benefits, worries about long term health repercussions, or worries about adverse effects cause many patients to stop treatment too soon. Non-adherence is also influenced by cultural norms and a lack of knowledge about how osteoporosis progresses. Treatment results are harmed as a result, raising the risk of fractures and associated problems. Long term patient involvement is challenging for healthcare practitioners, particularly when patients need daily or weekly oral medication. Enhancing patient education, providing alternate dosage regimens, and incorporating follow up assistance may all contribute to increased adherence and improved population wide therapeutic Treatment Persistence and AdherencePoor patient perseverance and adherence to prescribed treatment regimens is one of the main issues facing osteoporosis care in Saudi Arabia. Due to worries about side effects, worries about long term health repercussions, or a lack of obvious, immediate advantages, many patients stop treatment too soon. Non-adherence is further exacerbated by cultural attitudes and a lack of knowledge regarding the progressive nature of osteoporosis. Treatment results suffer as a result, and the risk of fractures and associated complications rises. It can be challenging for healthcare professionals to stay in touch with patients over the long term, particularly when they need daily or weekly oral medication. Enhancing follow up assistance, providing alternate dose schedules, and improving patient education may all contribute to increased adherence and improved therapeutic efficacy for the general public. Company Analysis: Overview, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis Amgen Inc. Eli Lilly and Company F. Hoffmann La Roche AG GlaxoSmithKline Plc Merck & Co. Inc. Novartis AG Pfizer Inc. Teva Pharmaceutical Industries Ltd. UCB S.A. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $210.89 Million Forecasted Market Value (USD) by 2033 $308.84 Million Compound Annual Growth Rate 4.3% Regions Covered Saudi Arabia Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Saudi Arabia Osteoporosis Drugs Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product Type6.2 By Route of Administration6.3 By States7. Product Type7.1 Bisphosphonates7.2 Calcitonin7.3 Rank Ligand Inhibitor7.4 Parathyroid Hormone Therapy (PTH)7.5 Selective Estrogen Receptor Modulators (SERMs)7.6 Sclerostin Inhibitor7.7 Others8. Route of Administration8.1 Oral8.2 Injectable8.3 Others9. Top States9.1 Dhahran9.2 Riyadh9.3 Khobar9.4 Jeddah9.5 Dammam9.6 Others10. Value Chain Analysis11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Pricing Benchmark Analysis13.1 Amgen Inc.13.2 Eli Lilly and Company13.3 F. Hoffmann-La Roche AG13.4 GlaxoSmithKline Plc13.5 Merck & Co. Inc.13.6 Novartis AG13.7 Pfizer Inc.13.8 Teva Pharmaceutical Industries Ltd.13.9 UCB S.A.14. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Osteoporosis Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
an hour ago
- Medscape
A Nurse in Every School?
As a school nurse, Traci Jones, RN, PhD, NCSN, handed out ice packs and bandages, but she also helped students manage chronic health conditions ranging from diabetes and asthma to seizure disorders and life-threatening allergies. 'There can't be an expectation that the teachers know how to identify healthcare issues,' said Jones, a school nurse administrator in Temple Hills, Maryland. '[There should be] a nurse in every school.' School nurses oversee case management, assist with individualized education plans for students with disabilities; implement public health strategies for immunizations, natural disasters, and school violence; and connect families with community health resources. Despite the essential role that school nurses play in ensuring the safety and well-being of schoolchildren, a growing number of districts do not have enough nurses to meet student needs. Data from the National Association of School Nurses (NASN) found that just 65% of schools had access to a registered nurse (RN), licensed practical nurse (LPN), or licensed vocational nurse. About Medscape Data Medscape continually surveys physicians and other medical professionals about key practice challenges and current issues, creating high-impact analyses. For example, the Medscape RN/LPN Job Market Report 2025 found that Both RNs and LPNs younger than 45 years were slightly more motivated to job search than older nurses. About 6 in 10 RNs and LPNs checked out a potential new job within the past 3 years. About 1 in 6 nurses don't think they have much negotiating power when it comes to getting a new job offer. Although 20 states, including Connecticut, Delaware, Massachusetts, and Minnesota, require K-12 schools to have a school nurse, students in other states often lack access to healthcare in school. Rural areas and districts in the Midwest and West employed the fewest number of school nurses, according to NASN. The Nurses for Under-Resourced Schools Everywhere (NURSE) Act was recently reintroduced in an effort to increase healthcare access in education. The legislation aims to establish a federal grant program to help Title I schools where at least 20% of students are enrolled in free- or reduced-price breakfast and lunch programs to hire and retain school nurses. 'The NURSE Act recognizes the critical role of school nurses in providing students with access to quality healthcare so they can be healthy, safe, and ready to learn,' explained NASN president-elect Pat Endsley, PhD, RN, NCSN, FNASN. More Than Bandages and Ice Packs Injuries, illnesses, and disabilities lead to chronic school absences for almost 6% of school-aged children, and school nurses can help manage acute and chronic illnesses that are linked with poor attendance. In schools without a school nurse, 18% of students were sent home for illnesses or injuries compared with just 5% of students in schools with a school nurse. School nurses don't just affect absenteeism. Studies have found that students with access to school nurses experience better management of chronic conditions and improved academic outcomes, too. 'Sometimes we're just that place where students can come for some reassurance…Sometimes they just need 5 minutes to come in and decompress before going back to class,' Endsley said. 'We're a safe place [and] our goal is getting that student back to class and getting the most out of their education.' However, providing healthcare and safe spaces in schools comes at a cost. On average, the cost of having an LPN in a school nursing program was $115,707 per school year at a time when US schools are facing their biggest budget crunch in years. Funding for school nurses comes from a patchwork of sources, including the federal Department of Education, Medicaid, state health departments, and grants. The patchwork approach leads to disparities in resources between states and even among school districts. Cuts to Medicaid and uncertainty about the future of the Board of Education could also affect the number of nurses in schools today. The expiration of Elementary and Secondary School Emergency Relief funding allocated during the COVID-19 pandemic led to severe implications in school districts that included job cuts and loss of critical programming, including the loss of school nurses. 'Schools got COVID funds to hire a lot of school nurses, but…after those funds expired, not very many schools made those positions permanent,' said Endsley. While previous recommendations from organizations like the American Academy of Pediatrics suggested a ratio of one school nurse for every 750 students, it's considered an outdated standard, according to Endsley. Instead, she believes districts should conduct ongoing assessments to determine student needs and inform hiring decisions. A school with 500 students but few chronic health conditions might need just one school nurse, while a less populated school with a higher proportion of students with ongoing medical needs might need two (or more) nurses, she explained. But there is more to addressing the school nurse shortage than coming up with student-to-nurse ratios. Changing Perceptions Hiring school nurses is challenging. Misconceptions about the role of school nurses and burnout are among the biggest reasons that 50% of RNs and LPNs leave school nursing in 3-6 months. 'Most people don't know what school nurses do,' said Jones. 'I've had people tell me, 'You sit at the desk all day and hand out candy.'' The perception that school nursing is all about 'Band-Aids, ice, and lice' prevents school nurses from entering the profession — but the RNs who work in school settings appreciate some of the perks: There are no weekend, rotating, or overnight shifts, and many school nurses work 10 months of the year, leading to better work-life balance. There are challenges, too. School nurses experience significant pay disparities. NASN data show that just 34% of school nurses make more than $60,000 per year compared with almost 70% of the total RN workforce. This often forces school nurses to pick up additional shifts in hospitals and clinics, Jones added. The workforce also tends to be older — more than two-thirds of school nurses are over 40 — and retire sooner, leading to greater turnover. The role is also best suited to mid-career nurses. Jones calls it 'grassroots nursing.' 'You have blood pressure cuffs and a stethoscope, and your own knowledge, judgment and skill set,' she added. 'You're usually the only medical expert in the building, and you need a solid foundation.' However, when RNs work in schools, sick and injured students aren't the only ones who benefit. Schools with full-time nurses receive an average return on investment of $1.59 for every dollar invested as well as significant savings in teacher, secretary, principal, and parent productivity — and the community benefits, too. 'School nurses really are an integral part of the whole education system,' Endsley said. 'We work in partnership with our school community, with our teachers, our administrators, but also with the community at large.'